small molecule

XTANDI

ENZALUTAMIDE

Loss of exclusivityFebruary 2037latest FDA-listed patent expiry

CompanyAstellas Pharma Us →See this company's full patent-cliff portfolio

Drug detail

Brand name	XTANDI
Active ingredient	ENZALUTAMIDE
Strength	40MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	August 2020
Marketing status	RX

Listed patents

Patent	Expires	Type
12161628	February 2037	use U-4104
12502357	September 2033	use U-4365
11839689	September 2033	product
7709517	August 2027	substance, product
8183274	August 2026	use U-3763
9126941	May 2026	use U-3763

Regulatory exclusivity

Code	Expires
I-926	November 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Astellas Pharma Us